inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.
Company profile
Ticker
NARI
Exchange
Website
CEO
William H. Hoffman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Inceptus Newco1 Inc.
SEC CIK
Corporate docs
Subsidiaries
Inari Medical International, Inc. • Inari Medical Latin America, Inc. • Inari Medical Australia • Inari Medical Distribuicao de Dispositivos Medicos Ltda. • Inari Medical Canada, Inc. • Inari Medical Costa Rica, S.A. • Inari Medical EU Limited • Inari Medical Asia PTE. LTD. • Inari Medical Europe GmbH • Inari Medical UK Limited ...
IRS number
452902923
NARI stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
25 Apr 24
ARS
2023 FY
Annual report to shareholders
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Inari Medical Reports Fourth Quarter 2023 Financial Results
28 Feb 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K/A
Limflow Consolidated Financial Statements
31 Jan 24
8-K
Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
9 Jan 24
Transcripts
NARI
Earnings call transcript
2023 Q4
28 Feb 24
NARI
Earnings call transcript
2023 Q3
1 Nov 23
NARI
Earnings call transcript
2023 Q2
2 Aug 23
NARI
Earnings call transcript
2023 Q1
3 May 23
NARI
Earnings call transcript
2022 Q4
27 Feb 23
NARI
Earnings call transcript
2022 Q3
2 Nov 22
NARI
Earnings call transcript
2022 Q2
4 Aug 22
NARI
Earnings call transcript
2022 Q1
5 May 22
NARI
Earnings call transcript
2021 Q4
24 Feb 22
NARI
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.18 mm | 89.18 mm | 89.18 mm | 89.18 mm | 89.18 mm | 89.18 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 217.92 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | 1.51 mm | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 87.68 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 402.3 | n/a | n/a |
Institutional ownership, Q3 2023
93.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 252 |
Opened positions | 33 |
Closed positions | 31 |
Increased positions | 97 |
Reduced positions | 88 |
13F shares | Current |
---|---|
Total value | 3.19 tn |
Total shares | 53.94 mm |
Total puts | 491.30 k |
Total calls | 139.91 k |
Total put/call ratio | 3.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.49 mm | $424.18 bn |
Wellington Management | 5.10 mm | $333.29 bn |
Vanguard | 4.71 mm | $308.21 bn |
BEN Franklin Resources | 2.84 mm | $185.72 bn |
CNVT CVF | 2.59 mm | $0.00 |
Cooperatieve Gilde Healthcare IV U.A. | 2.40 mm | $197.71 mm |
Alliancebernstein | 2.40 mm | $156.85 bn |
STT State Street | 1.76 mm | $115.02 bn |
Brown Advisory | 1.45 mm | $94.63 bn |
JPM JPMorgan Chase & Co. | 1.35 mm | $88.58 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Apr 24 | William Hoffman | Common Stock | Grant | Acquire A | No | No | 42.41 | 4,126 | 174.98 k | 1,003,908 |
24 Apr 24 | Rebecca Chambers | Common Stock | Grant | Acquire A | No | No | 42.41 | 4,126 | 174.98 k | 10,908 |
24 Apr 24 | Lucchese Cynthia L | Common Stock | Grant | Acquire A | No | No | 42.41 | 4,126 | 174.98 k | 38,429 |
24 Apr 24 | Mead Dana G Jr. | Common Stock | Grant | Acquire A | No | No | 42.41 | 4,126 | 174.98 k | 11,148 |
24 Apr 24 | Milder Donald B | Common Stock | Grant | Acquire A | No | No | 42.41 | 4,126 | 174.98 k | 259,126 |
News
What 8 Analyst Ratings Have To Say About Inari Medical
12 Apr 24
Canaccord Genuity Maintains Buy on Inari Medical, Maintains $75 Price Target
12 Apr 24
Inari Medical To Replace Callon Petroleum In S&P SmallCap 600, Effective Prior To The Opening Of Trading On Monday, April 1
25 Mar 24
Forecasting The Future: 7 Analyst Projections For Inari Medical
22 Mar 24
Truist Securities Maintains Hold on Inari Medical, Lowers Price Target to $52
22 Mar 24
Press releases
Investor News Announces Civil Investigative Demand Served to Inari Medical by U.S. Department of Justice – Contact Johnson Fistel, LLP
25 Apr 24
Lowey Dannenberg, P.C. is Investigating Inari Medical Inc. ("Inari" or the "Company") (NASDAQ:NARI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
22 Apr 24
Lowey Dannenberg, P.C. is Investigating Inari Medical Inc. ("Inari" or the "Company") (NASDAQ:NARI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
19 Apr 24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm
18 Apr 24
Inari Medical to Announce First Quarter 2024 Financial Results
17 Apr 24